Zyrova Gold 10 Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Rosuvastatin (10 mg), and Clopidogrel (75 mg), indicated for the prevention and management of cardiovascular diseases. Aspirin, a well-known antiplatelet agent, inhibits cyclooxygenase enzymes, thereby reducing thromboxane A2 synthesis and preventing platelet aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), contributing to the reduction of atherosclerotic plaque progression. Clopidogrel, another antiplatelet agent, selectively inhibits the P2Y12 component of ADP receptors on platelet surfaces, preventing activation of the GPIIb/IIIa receptor complex and subsequent platelet aggregation. The combined action of these agents provides synergistic benefits in reducing the risk of myocardial infarction, stroke, and other thrombotic cardiovascular events in patients with established coronary artery disease or at high risk. Zyrova Gold 10 Capsule should be administered under medical supervision, with careful monitoring for potential adverse effects such as bleeding, hepatic dysfunction, or hypersensitivity reactions. It is contraindicated in patients with active bleeding, severe liver impairment, or known hypersensitivity to any component. Regular follow-up and laboratory assessments are recommended to ensure therapeutic efficacy and safety.